The double life of cardiac mesenchymal cells: Epimetabolic sensors and therapeutic assets for heart regeneration

Chiara Cencioni, Sandra Atlante, Matteo Savoia, Fabio Martelli, Antonella Farsetti, Maurizio C Capogrossi, Andreas M Zeiher, Carlo Gaetano, Francesco Spallotta

Research output: Contribution to journalArticle

Abstract

Organ-specific mesenchymal cells naturally reside in the stroma, where they are exposed to some environmental variables affecting their biology and functions. Risk factors such as diabetes or aging influence their adaptive response. In these cases, permanent epigenetic modifications may be introduced in the cells with important consequences on their local homeostatic activity and therapeutic potential. Numerous results suggest that mesenchymal cells, virtually present in every organ, may contribute to tissue regeneration mostly by paracrine mechanisms. Intriguingly, the heart is emerging as a source of different cells, including pericytes, cardiac progenitors, and cardiac fibroblasts. According to phenotypic, functional, and molecular criteria, these should be classified as mesenchymal cells. Not surprisingly, in recent years, the attention on these cells as therapeutic tools has grown exponentially, although only very preliminary data have been obtained in clinical trials to date. In this review, we summarized the state of the art about the phenotypic features, functions, regenerative properties, and clinical applicability of mesenchymal cells, with a particular focus on those of cardiac origin.

Original languageEnglish
Pages (from-to)43-55
Number of pages13
JournalPharmacology and Therapeutics
Volume171
DOIs
Publication statusE-pub ahead of print - Oct 11 2016

Fingerprint

Regeneration
Therapeutics
Pericytes
Epigenomics
Fibroblasts
Clinical Trials

Keywords

  • Journal Article
  • Review

Cite this

Cencioni, C., Atlante, S., Savoia, M., Martelli, F., Farsetti, A., Capogrossi, M. C., ... Spallotta, F. (2016). The double life of cardiac mesenchymal cells: Epimetabolic sensors and therapeutic assets for heart regeneration. Pharmacology and Therapeutics, 171, 43-55. https://doi.org/10.1016/j.pharmthera.2016.10.005

The double life of cardiac mesenchymal cells : Epimetabolic sensors and therapeutic assets for heart regeneration. / Cencioni, Chiara; Atlante, Sandra; Savoia, Matteo; Martelli, Fabio; Farsetti, Antonella; Capogrossi, Maurizio C; Zeiher, Andreas M; Gaetano, Carlo; Spallotta, Francesco.

In: Pharmacology and Therapeutics, Vol. 171, 11.10.2016, p. 43-55.

Research output: Contribution to journalArticle

Cencioni, C, Atlante, S, Savoia, M, Martelli, F, Farsetti, A, Capogrossi, MC, Zeiher, AM, Gaetano, C & Spallotta, F 2016, 'The double life of cardiac mesenchymal cells: Epimetabolic sensors and therapeutic assets for heart regeneration', Pharmacology and Therapeutics, vol. 171, pp. 43-55. https://doi.org/10.1016/j.pharmthera.2016.10.005
Cencioni, Chiara ; Atlante, Sandra ; Savoia, Matteo ; Martelli, Fabio ; Farsetti, Antonella ; Capogrossi, Maurizio C ; Zeiher, Andreas M ; Gaetano, Carlo ; Spallotta, Francesco. / The double life of cardiac mesenchymal cells : Epimetabolic sensors and therapeutic assets for heart regeneration. In: Pharmacology and Therapeutics. 2016 ; Vol. 171. pp. 43-55.
@article{0f03b4f7f8fe4c12835459a8d4664a29,
title = "The double life of cardiac mesenchymal cells: Epimetabolic sensors and therapeutic assets for heart regeneration",
abstract = "Organ-specific mesenchymal cells naturally reside in the stroma, where they are exposed to some environmental variables affecting their biology and functions. Risk factors such as diabetes or aging influence their adaptive response. In these cases, permanent epigenetic modifications may be introduced in the cells with important consequences on their local homeostatic activity and therapeutic potential. Numerous results suggest that mesenchymal cells, virtually present in every organ, may contribute to tissue regeneration mostly by paracrine mechanisms. Intriguingly, the heart is emerging as a source of different cells, including pericytes, cardiac progenitors, and cardiac fibroblasts. According to phenotypic, functional, and molecular criteria, these should be classified as mesenchymal cells. Not surprisingly, in recent years, the attention on these cells as therapeutic tools has grown exponentially, although only very preliminary data have been obtained in clinical trials to date. In this review, we summarized the state of the art about the phenotypic features, functions, regenerative properties, and clinical applicability of mesenchymal cells, with a particular focus on those of cardiac origin.",
keywords = "Journal Article, Review",
author = "Chiara Cencioni and Sandra Atlante and Matteo Savoia and Fabio Martelli and Antonella Farsetti and Capogrossi, {Maurizio C} and Zeiher, {Andreas M} and Carlo Gaetano and Francesco Spallotta",
note = "Copyright {\circledC} 2016 Elsevier Inc. All rights reserved.",
year = "2016",
month = "10",
day = "11",
doi = "10.1016/j.pharmthera.2016.10.005",
language = "English",
volume = "171",
pages = "43--55",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The double life of cardiac mesenchymal cells

T2 - Epimetabolic sensors and therapeutic assets for heart regeneration

AU - Cencioni, Chiara

AU - Atlante, Sandra

AU - Savoia, Matteo

AU - Martelli, Fabio

AU - Farsetti, Antonella

AU - Capogrossi, Maurizio C

AU - Zeiher, Andreas M

AU - Gaetano, Carlo

AU - Spallotta, Francesco

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2016/10/11

Y1 - 2016/10/11

N2 - Organ-specific mesenchymal cells naturally reside in the stroma, where they are exposed to some environmental variables affecting their biology and functions. Risk factors such as diabetes or aging influence their adaptive response. In these cases, permanent epigenetic modifications may be introduced in the cells with important consequences on their local homeostatic activity and therapeutic potential. Numerous results suggest that mesenchymal cells, virtually present in every organ, may contribute to tissue regeneration mostly by paracrine mechanisms. Intriguingly, the heart is emerging as a source of different cells, including pericytes, cardiac progenitors, and cardiac fibroblasts. According to phenotypic, functional, and molecular criteria, these should be classified as mesenchymal cells. Not surprisingly, in recent years, the attention on these cells as therapeutic tools has grown exponentially, although only very preliminary data have been obtained in clinical trials to date. In this review, we summarized the state of the art about the phenotypic features, functions, regenerative properties, and clinical applicability of mesenchymal cells, with a particular focus on those of cardiac origin.

AB - Organ-specific mesenchymal cells naturally reside in the stroma, where they are exposed to some environmental variables affecting their biology and functions. Risk factors such as diabetes or aging influence their adaptive response. In these cases, permanent epigenetic modifications may be introduced in the cells with important consequences on their local homeostatic activity and therapeutic potential. Numerous results suggest that mesenchymal cells, virtually present in every organ, may contribute to tissue regeneration mostly by paracrine mechanisms. Intriguingly, the heart is emerging as a source of different cells, including pericytes, cardiac progenitors, and cardiac fibroblasts. According to phenotypic, functional, and molecular criteria, these should be classified as mesenchymal cells. Not surprisingly, in recent years, the attention on these cells as therapeutic tools has grown exponentially, although only very preliminary data have been obtained in clinical trials to date. In this review, we summarized the state of the art about the phenotypic features, functions, regenerative properties, and clinical applicability of mesenchymal cells, with a particular focus on those of cardiac origin.

KW - Journal Article

KW - Review

U2 - 10.1016/j.pharmthera.2016.10.005

DO - 10.1016/j.pharmthera.2016.10.005

M3 - Article

C2 - 27742569

VL - 171

SP - 43

EP - 55

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -